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Background: Several encouraging phase III clinical trials have evaluated platinum-based induction chemotherapy
against stage IIB-IIIA non-small-cell lung cancer (NSCLC). Chemotherapy efficacy was assessed using common
regimens in this retrospective analysis.
Methods: From 2007 to 2011, the clinical records of stage IIB-IIIA NSCLC patients undergoing surgery after
neoadjuvant chemotherapy were reviewed. Gathered data were tested for significance and variables impacting
survival were assessed by univariate and Cox regression analyses.
Results: Overall, 84% of patients were male and 93% had central disease. Platinum-based chemotherapy protocols
with gemcitabine or paclitaxel gave an overall response rate of 55% (45/82) and 6.1% pathological complete
response (5/82). Clinical response was unassociated with regimen or histology, while more pneumonectomies were
performed in the stable compared to partial response disease group (P =0.040). Postoperative mortality was 1.2%
(1/82), and complications, unassociated with regimen or histology, were atelectasis (26.8%) and supraventricular
arrhythmias (13.4%). Right-sided procedures appeared to increase the incidence of bronchopleural fistula (P =0.073).
The median disease-free survival time was 18 months and median overall survival time was not reached.
Disease-free survival rates at one, two, and three years were 54%, 47%, and 33%, while the overall survival rate was
73%, 69%, and 59%, respectively. Disease-free survival predictors were radiographic response and mediastinal
lymphadenopathy before chemotherapy (P =0.012 and 0.002, respectively).
Conclusions: Two cycles of platinum-based chemotherapy with gemcitabine or paclitaxel is efficacious for patients
with stage IIB-IIIA central disease. Patients achieving clinical response had improved disease-free survival times,
while those with mediastinal lymphadenopathy had a higher postoperative recurrence risk.
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Lung cancer in stage IIB-IIIA generally has an unfavor-
able prognosis, with poor five-year survival rates ranging
from 19 to 25% for those using clinical stage prediction
and 24 to 36% for those using pathological stage predic-
tion, respectively [1]. Complete surgical resection has a* Correspondence: zlyangyue@bjmu.edu.cn
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reproduction in any medium, provided the orlow survival and high recurrence rate, although effective
systemic therapies, including perioperative chemother-
apy, radiation and combined modality therapies, have
shown potential benefits in numerous clinical trials.
Following surgery, neoadjuvant chemotherapy has the po-
tential advantage of reducing tumor volume and eradicating
micrometastatic disease, thereby improving the outcome.
However, the Medical Research Council (MRC) LU22 trial
in 2007, which evaluated the role of induction chemother-
apy prior to surgery, failed to show evidence of a difference
in overall survival (OS) between neoadjuvant chemotherapyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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519 patients with stages IA-IIIB lung cancer, of whom 61%
had stage IA or IB disease, received either surgery alone
or a combination of surgery with one of six chemotherapy
regimens [2]. Three years later, the Southwest Oncology
Group (SWOG) 9900 trial, aimed at evaluating the efficacy
of preoperative paclitaxel and carboplatin, achieved a trend
toward improved OS (Hazard Ratio = 0.79) and disease-
free survival (DFS) (HR = 0.80) in the induction chemo-
therapy arm [3]. The (Neo)Adjuvant Taxol/Carboplatin
Hope (NATCH) trial included 624 patients with stage IA,
IB, II, or IIIA(T3N1) NSCLC. This study finally demon-
strated that no statistically significant differences in DFS
were found with the addition of either preoperative or adju-
vant chemotherapy to surgery [4]. However, a meta-analysis
of 13 randomized control trials published in the same year
concluded that neoadjuvant chemotherapy would improve
the OS of operable NSCLC patients, including patients
with stage III disease [5]. The recently published Chemo-
therapy in Early Stages Trial (ChEST), yielded a significant
improvement in both DFS (HR = 0.51) and OS (HR = 0.42)
in patients with clinical stage IIB-IIIA NSCLC using pre-
operative gemcitabine plus cisplatin [6].
Based on the above findings, we retrospectively reviewed
all cases of clinical stage IIB-IIIA NSCLC whose treatment
included a platinum-based induction therapy prior to sur-
gery at our center, from the past five years, in order to
comprehensively analyze the efficacy, potential complica-
tions and impact on survival of this treatment modality.
Methods
Patients and methods
We retrospectively reviewed the clinical records of patients
who underwent surgery for NSCLC following neoadjuvant
chemotherapy at Peking University Cancer Hospital from
January 2007 to December 2011. All the patients had been
diagnosed with NSCLC by means of biopsy, and a pretreat-
ment evaluation was performed which included a chest
computed tomography (CT) scan, a magnetic resonance
imaging (MRI) scan of the brain and a bone scan in
addition to an ultrasound examination of the abdomen
and supraclavicular lymph nodes. Positron emission tom-
ography - computed tomography (PET/CT) scans were
not routinely used. By searching our database, patients
were selected for this study based on the following features:
(1) presence of central disease with T2bN1, T3 or T4 N0
to N1, or locally advanced disease with T1 to T3 N2; (2)
had undergone at least two cycles of platinum-based che-
motherapy preoperatively; (3) had no advanced disease
such as N3 or M1; and (4) had not received radiotherapy
as induction therapy. Clinical variables were recorded in
detail including age, sex, histological type, clinical TNM
stage, disease location, chemotherapy regimen, clinical re-
sponse, type of resection, postoperative complications, finalpathological TNM stage, disease recurrence and survival.
Specifically, long-term survival and follow-up data were
obtained from either electronic medical records or the
medical statistics office. If survival or death could not be
confirmed, a telephone interview was carried out in order
to obtain the information.
Treatment
All patients received platinum-based chemotherapy in one
department of the hospital. Treatment consisted of gem-
citabine (1,250 mg/m2 on days one and eight) followed by
cisplatin (75 mg/m2on day one) or carboplatin at a dose to
achieve an area under the concentration-time curve (AUC)
of 5 mg/mL on day one, with treatments being repeated
every 21 days. Another commonly used regimen was pac-
litaxel (175 mg/m2 on day one) combined with cisplatin
or carboplatin at the same dose as described above. A fur-
ther neoadjuvant chemotherapy regimen was pemetrexed
(500 mg/m2 on day one) followed by cisplatin.
Response to the induction treatment was evaluated
using CT scans at least two weeks after chemotherapy.
The efficacy was classified as complete response (CR), par-
tial response (PR), stable disease (SD) or progressive dis-
ease (PD) according to the World Health Organization
(WHO) criteria. The presence of lymphadenopathy in the
mediastinum (cN2) is defined as lymph nodes greater than
2.0 cm on the long axis view or 1.0 cm on the short axis




























Table 3 Complications associated with possible risk
factors
Variables Complications
Atelectasis Arrhythmias Bronchopleural fistula
Laterality
right side 9 5 3
Left side 13 6 0
P-value 0.859 0.831 0.073
Induction regimen
gemcitabine 11 5 1
paclitaxel 10 4 2
P-value 0.431 0.731 0.557
Type of resection
pneumonectomy NEa 3 1
lobectomy NE 6 2
P-value NE 0.387 0.513
NEa: not evaluable as ipsilateral atelectasis could not occur.
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weeks by the same surgical team, on the thoracic unit,
after the completion of induction chemotherapy. System-
atic mediastinal lymph node dissection, rather than lymph
node sampling, consisted of levels 2, 3, 4, 7, 8, 9, 10 and
11 on the right as well as 4, 5, 6, 7, 8, 9, 10, 11 on the
left. We also resected lobar nodes (level 12), segmental
nodes (level 13) and subsegmental nodes (level 14) for ac-
curate staging. Complete resection (R0) was defined as
free resection margins with systematic nodal dissection
showing the highest mediastinal node being negative, with
no extracapsular nodal extension of the tumor. The final
pathological examination and analysis was carried out in
the same hospital department, and pathological complete
response (pCR) was defined as no viable tumor cells in the
specimen, as determined by light microscopy. Any com-
plications after the operation were carefully recorded.
Statistical analysis
Statistical analysis was performed using patched SPSS
17.0 for Windows software (SPSS Inc., Chicago, IL, USA).
Data were tested for significance with the χ2 or Fisher’s
exact test for discrete variables, and with the t-test for
continuous variables. OS and DFS were estimated using
the Kaplan-Meier method. The impact on survival of vari-
ables was assessed using univariate analysis in order to se-
lect related clinical variables and the log-rank test and
Cox regression analysis to identify the effect of the covari-
ates. Results of analyses were considered significant at a
level of P< 0.05.
Results
Between 2007 and 2011, 98 patients underwent surgery
following neoadjuvant chemotherapy, of which 82 cases
were considered for inclusion in this retrospectiveTable 4 Clinical response rate and pCR rate with different
regimens
Variables Radiographic response
CR/PR SD/PD RRa P-value pCR
All patients(n=82b) 45 37 55% 5(6%)
gemcitabine 24 21 53% 2(4%)
paclitaxel 18 11 62% 0.309 3(10%)
squamous (n=51) 29 22 57% 4(8%)
gemcitabine 18 14 56%
paclitaxel 11 8 58% 0.572
adenocarcinoma (n=29) 15 14 52% 1(3%)
gemcitabine 6 6 50%
paclitaxel 6 3 67%
pemetrexed 3 5 38% 0.517
aRR: response rate.
bNote: Eight of the 82 patients who received pemetrexed were excluded in
the comparison between gemcitabine and paclitaxel because pemetrexed was
used only in patients with adenocarcinoma.
Figure 2 (A) Kaplan-Meier DFS, median DFS time was 18 months (95%
two, and three years was 54%, 47%, and 33%, respectively (left pane
one, two, and three years was 73%, 69%, and 59%, respectively (right pane
panel) after adjustment for other factors.
Figure 1 Among 72 patients with central disease from NSCLC,
43 patients achieved radiographic response. Of these patients,
only six underwent pneumonectomy, which was significantly fewer
than those with stable disease(6/43 versus 10/29, P =0.040).
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as N3 or M1 at diagnosis, six received induction regi-
mens other than cisplatin or carboplatin, and two pa-
tients received just one treatment cycle preoperatively; a
further two patients were excluded due to having re-
ceived induction radiotherapy. The clinical characteris-
tics of the selected 82 patients prior to treatment are
given in Table 1. In general, this cohort of patients was
male with central squamous carcinoma commonly diag-
nosed by bronchoscopy. Most patients received two cycles
of gemcitabine (55%) or paclitaxel (35%), in combination
with cisplatin (82%) or carboplatin (18%). Resections
consisted of 16 pneumonectomies (20%), 52 lobectomies
(63%), eight bilobectomies (10%) and two wedge resec-
tions (2%). A thoracotomy and exploration at the time of
operation was performed on a further four patients (5%)
due to unresectability or pleural dissemination. Of the pa-
tients who received resections, 20 underwent sleeve lobec-
tomy or bronchoplasty, two underwent carinal resection
with right pneumonectomy, eight underwent angioplastycumulative survival 0.6 to 35.4 months), the DFS rate at one,
l). Kaplan-Meier OS, median OS time was not reached, the OS rate at
l). (B) DFS differences in cN2 (left panel) and clinical response (right
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another seven patients underwent broncho-angioplastic
(sleeve) lobectomies. R0 resection was documented in 76
patients (93%); the remaining patients had R1 or R2 resec-
tion. The treatment regimens are shown in Table 2.
No patients died intraoperatively but one patient died
within 30 days of surgery due to respiratory failure fol-
lowing a bronchovascular sleeve resection: the overall
postoperative mortality was 1.2%. Regarding postopera-
tive morbidity, the most common complications were
atelectasis (26.8%) and supraventricular arrhythmias
(13.4%). Bronchopleural fistulas were recorded in three
patients: one of whom underwent right pneumonec-
tomy, one underwenta right middle and lower lobec-
tomy, and one had a right lower lobectomy. Other
complications included one case each of chylothorax,
empyema and pneumonia. There were no hemothoraces
requiring reexploration or cases of pulmonary embolism
after surgery, and the total postoperative morbidity was
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SD/PDdifferent neoadjuvant chemotherapy regimens, type of
resection, and laterality was performed. No apparent dif-
ferences in complications were noted between patients
who received gemcitabine or paclitaxel combined with
platinum, nor was the type of surgery a significant fac-
tor. However, a right-sided procedure was associated
with an increased trend towards bronchopleural fistula,
although the difference was not statistically significant
(P= 0.073) (data shown in Table 3).
The radiographic response of the primary tumor to in-
duction chemotherapy was evaluated. CR was observed in
11% of patients (9/82), while PR was noted in 44% of pa-
tients (36/82), resulting in an overall response rate of 55%.
37 patients with SD and no PD were assessed. Pathological
response was evaluated with five pCR being confirmed, in-
cluding four CR and one PR by clinical evaluation. The
pCR rate was 6.1%. The response to treatment with the
two major chemotherapy schedules (gemcitabine and pacli-
taxel) was not significantly different (P = 0.309). Subset ana-
lyses are summarized in Table 4 and showed no significantsurvival (DFS)
HR 95% CI P-value
0.845 0.425 to1.680 0.632
2.133 0.954 to4.769 0.065
2.191 1.088 to4.409 0.028
0.466 0.227 to0.957 0.038
0.645 0.289 to1.440 0.285
0.186 0.073 to0.474 0.0004
0.654 0.329 to1.301 0.226
1.403 0.576 to3.419 0.456
0.561 0.245 to 1.287 0.173
1.249 0.833 to1.873 0.283
1.647 0.804 to3.373 0.172
0.179 0.060 to0.531 0.002
0.295 0.114 to0.766 0.012
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and pemetrexed for the major histological types (squamous
and adenocarcinoma), (P= 0.572, 0.517, respectively).
Seventy-two patients were identified with central disease
and underwent resection surgery (10 cases were excluded
either due to having undergone exploration only or to the
presence of peripheral disease). Among these patients, 43
had a radiographic response (PR/CR), while 29 patients had
stable disease. There was no significant difference in T size
before chemotherapy between the two groups (P= 0.739),
although more pneumonectomies were performed in the
patients with stable disease (P = 0.04) (Figure 1).
Among the 82 patients, 54 had a follow-up time of
more than 18 months and these were evaluated. The
median follow-up time was 38.6 months, with a median
DFS time of 18 months (95% cumulative survival, 0.6 to
35.4 months)and median OS time was not reached dur-
ing the study's follow-up period (Figure 2A). The DFS
rate at one, two, and three years was 54%, 47%, and 33%,
while the OS rate was 73%, 69%, and 59%, respectively.
In a univariate analysis, the effects of several factors on
DFS were evaluated, including age, sex, histological type,
neoadjuvant chemotherapy regimen, radiographic response
and radiographic T size before chemotherapy, lymphade-
nopathy in the mediastinum before chemotherapy (cN2),
radiographic T size after chemotherapy, type of resection,
pathological mediastinal lymph node metastasis (pN2)
and pathological lymph node metastasis (pN1/N2). Three
univariate predictors of DFS were identified: histological
type, neoadjuvant chemotherapy regimen and mediastinalFigure 3 Tumor in the left upper lobe (A) presented a CR after two cy
(B), although pathological examination found residual viable tumor b
a PR after two cycles of paclitaxel plus cisplatin induction therapy (E), while
was replaced by abundant foamy cells and lymphocytic infiltration (F).lymphadenopathy (cN2). Male patients, a clinical response
to therapy, T size less than 30 mm after chemotherapy, and
pathological N0, all showed improved DFS times. Univari-
ate predictors with P-values of at least 0.25 were entered
into a multivariate model. Ultimately, we identified radio-
graphic response (P = 0.012), along with cN2 (P= 0.002) as
predictors of DFS. The HRs, respective 95% confidence in-
tervals (CI) and P-values are summarized in Table 5. As
shown in Figure 2B, the survival curves demonstrate sig-
nificant differences between cN2+ and cN2- (left panel)
and between CR+PR and SD+PD (right panel).
Discussion
Central lung cancer with or without mediastinal lymph-
adenopathy is a problem that thoracic surgeons continue
to face. Direct resection of the tumor is challenging, incur-
ring a high risk of massive hemorrhage and the discovery
of intraoperative unresectability. In our retrospective re-
view, 93% of patients had central disease (76/82) of whom
48% (39/82) had, at diagnosis, involvement of central great
vessels such as the pulmonary artery, pulmonary vein or
superior vena cava. 35% (29/82) of patients had atelectasis
or the possibility of requiring pneumonectomy if resected
directly. In a survival analysis, it has been proven that
complete resections have a favorable impact on survival
compared to incomplete resections [7], even in the case
of mediastinal invasion T4 disease [8]. Surgery also offers
improved local control rates and OS when compared to
radiotherapy following induction therapy [9,10], indicating
that R0 resection remains the cornerstone of treatmentcles of induction chemotherapy with gemcitabine plus cisplatin
y light microscopy (C). Another tumor in left lower lobe (D) achieved
no cancer cells were seen in the residual specimen, and all the tumor
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93%, which is similar to that found in previous trials (77.4
to 93%) [3,7,11,12]. Although this is a retrospective study
and the results would be diminished if the overall intent-
to-treat (ITT) population were considered, this high R0
resection rate is still promising for cases of locally ad-
vanced central disease after chemotherapy. Clearly, pa-
tients with the above features present more intraoperative
technical challenges to the thoracic surgeon and require
more careful postoperative care from surgeons who have
considerable experience in handling this patient popula-
tion [13]. In our study, the 1.2% overall postoperative
mortality is encouraging and lower than that previously
reported (3 to 5%) [3,6,7]. Postoperative complications
were acceptable and there were no differences observedFigure 4 This patient with left upper lobe lung cancer had a high risk
pulmonary artery (A). However, after two cycles of induction chemothera
of the upper lobe bronchus and the first branch of pulmonary artery, no si
Finally, the procedure of lobectomy was performed without angioplasty orbetween chemotherapy regimens and the types of resec-
tion. All three bronchopleural fistula cases occurred in
right-sided procedures. This is consistent with previous
results where neoadjuvant chemotherapy when followed
by a right-sided procedure, especially a pneumonectomy,
is an important causal factor of bronchopleural fistula
[14]. We conclude that the local intrinsic anatomy may be
responsible for the fistula if the procedure included a right
lower lobectomy, while induction therapy is another factor
that hampers bronchial stump healing.
We observed a comparable response rate of 55% and a
pCR rate of 6.1%, which are within the ranges of those
reported [6,7,15-17]. The pCR rate is considered to be
an important predictor of survival in patients receiving
induction chemotherapy followed by surgical resectionof pneumonectomy if resected directly due to involvement of
py, the tumor achieved significant remission (B). During the isolation
gnificant invasion was encountered at the proximal portion (C, D).
bronchoplasty (E).
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dict pCR is disappointing, with a high false negative rate
of approximately 50% by CT and 30% by PET/CT [19].
In our study of nine cases with radiographic CR, only
four (44%) were confirmed pCR with another one case
confirmed from the radiographic PR cohort. This implies
that surgical resection cannot be avoided following in-
duction therapy since the rate of complete clearance of
tumor using chemotherapy is low and difficult to predict
preoperatively (Figure 3). Gemcitabine and paclitaxel
were two major regimens used as induction therapy in
our study which, in previous studies, had given good re-
sponse rates for preoperative chemotherapy, ranging
from 35 to 70.2% [6,17,20] and 41 to 56% [3,4,20], re-
spectively. Our analysis showed similar results with a
53% response rate with gemcitabine and 62% with pacli-
taxel. In addition, we compared these regimens in differ-
ent histological types, finding no significant difference inFigure 5 To resect this centrally located tumor is also challenging (A)
possible to preserve lung tissue and avoid pneumonectomy (B). Durin
isolated and controlled (C). Finally, the procedure of right middle and lowe
margin was found to be free of tumor (E).response rate. This result is consistent with that reported
in The Eastern Cooperative Oncology Group (ECOG)
1594 trial and other retrospective analyses of advanced
disease aimed at comparing efficacy by histological type
using different regimens [21-23]. This suggests the choice
of induction regimen cannot be made by considering
tumor histological type alone, and further studies are re-
quired to match candidates with the appropriate regimen
in order to achieve the expected response rate. Ribonucle-
otide reductase M1 (RRM1) and thymidylate synthase
(TS) mRNA levels were once reported to be predictive of
disease response and considered useful parameters for the
treatment selection of gemcitabine or pemetrexed. This
observation suggested promising potential for further re-
search in this field [24].
Whether and to what extent neoadjuvant chemother-
apy could change the type of resection or even enable
treatment of unresectable disease remains controversial, but two cycles of gemcitabine combined with cisplatin made it
g the resection, the right main pulmonary artery was successfully
r lobectomy with bronchoplasty was performed (D), and the arterial
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based on radiographic images which are subjective and
highly dependent on the experience and expertise of the
thoracic surgeon [13], and the type of surgery cannot be de-
termined until an intraoperative exploration is performed.
MRC-LU22 once reported that a small proportion of pa-
tients (about 5%) were able to undergo a lobectomy rather
than a pneumonectomy as a result of neoadjuvant chemo-
therapy [2]. In all cases of central disease that had been
resected, we observed that the number of successful pneu-
monectomies was significantly higher in the SD group than
in the CR or PR group (P= 0.040). Two cases of un-
resectable disease occurred in the former group, which
supports the possible theory that potential pneumonec-
tomies for unresectable disease could be avoided in favor
of bronchoplasty or angioplasty procedures by means ofFigure 6 The upper right pleural cavity was occupied by a large squa
After neoadjuvant chemotherapy, the tumor shrank significantly (B). Althou
anterior was exposed and isolated successfully (D). Finally, the patient undeefficacious preoperative chemotherapy. Although a clinical
trial designed to confirm this function of induction therapy
would not be possible, we believe that induction chemo-
therapy facilitates and simplifies the surgery of patients with
central disease as illustrated in Figures 4, 5, and 6. Many
studies have reported that pneumonectomy was one of the
major factors influencing outcome in patients with locally
advanced NSCLC after induction chemotherapy [14,15,25].
Statistically significant differences were observed in postop-
erative mortality for pneumonectomies (11.3%) compared
with lobectomies (2.4%), especially for right pneumonecto-
mies [26]. Furthermore, a low compliance rate in accepting
postoperative adjuvant chemotherapy was observed in pa-
tients who underwent a pneumonectomy [27]. Therefore,
in our center, given the considerable abnormalities in the
respiratory and cardiovascular systems in our patients,mous carcinoma, and the right hilum had also been invaded (A).
gh the induction therapy created fibrosis in the hilum (C), the truncus
rwent right upper lobe sleeve resection without angioplasty (E).
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ceive adjuvant chemotherapy or radiotherapy due to the
potential toxicity risk of these treatments. Despite this,
neither excess morbidity nor shortened DFS were found in
this cohort; findings which we attributed to good postoper-
ative care, reasonable patient selection and appropriate in-
duction chemotherapy.
The OS rates of 73% at one year and 59% at three
years were within the range of those reported by previ-
ous studies which included all the pathological stages
[3,6,12]. These represent the reality of clinical practice
in our center. Because the median OS time was not
reached in our study, we focused on DFS time which is
closely linked to surgery and perioperative therapy. In
previous retrospective studies, it has been demonstrated
that age, complete resection, pneumonectomy and path-
ological stage all had a significant impact on survival
[7,15,16,25]. In addition to these factors, mediastinal
downstaging is another important determinant of sur-
vival, particularly for stage IIIA disease [16,28]. During
our study, downstaging was not considered due to the
unreliable evaluation of clinical nodal (cN) status by CT.
We noted a trend toward difference in DFS for patho-
logical nodal (pN) status, although this was not statisti-
cally significant (P= 0.172). However, we observed that
patients displaying central disease with mediastinal
lymphadenopathy had a high postoperative risk of recur-
rence unless a pN0 status was achieved with induction
chemotherapy.
Conclusion
This is a retrospective review of a group of patients charac-
terized by having central disease from clinical stage IIB-IIIA
non-small-cell lung cancer and who had received two cycles
of platinum-based chemotherapy prior to surgical resection.
Although the study was potentially limited due to the small
number of patients, short follow-up period and unreliable
N staging before chemotherapy, we achieved a comparable
response rate and pCR rate with a high R0 resection and
low mortality rate, demonstrating the feasibility and efficacy
of this relatively simple but standard treatment model. The
good clinical response might have had some influence on
avoiding pneumonectomy and unresectability. Additionally,
we found that radiographically stable disease, together with
cN2, was considered an adverse factor for DFS.
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